EGFR and non-small cell lung carcinoma: Erlotinib is the standard therapy for advanced NSCLC with EGFR mutation and has also been approved for the treatment of unselected chemorefractory advanced NSCLC and for maintenance therapy following first-line chemotherapy (7).